• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用人工智能识别非小细胞肺癌肿瘤微环境异质性。

Using Artificial Intelligence to Identify Tumor Microenvironment Heterogeneity in Non-Small Cell Lung Cancers.

机构信息

Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.

Markey Cancer Center, University of Kentucky, Lexington, Kentucky; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky.

出版信息

Lab Invest. 2023 Aug;103(8):100176. doi: 10.1016/j.labinv.2023.100176. Epub 2023 May 12.

DOI:10.1016/j.labinv.2023.100176
PMID:37182840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10527157/
Abstract

Lung cancer heterogeneity is a major barrier to effective treatments and encompasses not only the malignant epithelial cell phenotypes and genetics but also the diverse tumor-associated cell types. Current techniques used to investigate the tumor microenvironment can be time-consuming, expensive, complicated to interpret, and often involves destruction of the sample. Here we use standard hematoxylin and eosin-stained tumor sections and the HALO AI nuclear phenotyping software to characterize 6 distinct cell types (epithelial, mesenchymal, macrophage, neutrophil, lymphocyte, and plasma cells) in both murine lung cancer models and human lung cancer samples. CD3 immunohistochemistry and lymph node sections were used to validate lymphocyte calls, while F4/80 immunohistochemistry was used for macrophage validation. Consistent with numerous prior studies, we demonstrated that macrophages predominate the adenocarcinomas, whereas neutrophils predominate the squamous cell carcinomas in murine samples. In human samples, we showed a strong negative correlation between neutrophils and lymphocytes as well as between mesenchymal cells and lymphocytes and that higher percentages of mesenchymal cells correlate with poor prognosis. Taken together, we demonstrate the utility of this AI software to identify, quantify, and compare distributions of cell types on standard hematoxylin and eosin-stained slides. Given the simplicity and cost-effectiveness of this technique, it may be widely beneficial for researchers designing new therapies and clinicians working to select favorable treatments for their patients.

摘要

肺癌异质性是有效治疗的主要障碍,不仅包括恶性上皮细胞表型和遗传学,还包括多种与肿瘤相关的细胞类型。目前用于研究肿瘤微环境的技术可能既耗时、昂贵、解释复杂,又常常涉及样本的破坏。在这里,我们使用标准的苏木精和伊红染色肿瘤切片和 HALO AI 核表型分析软件,对两种小鼠肺癌模型和人类肺癌样本中的 6 种不同的细胞类型(上皮细胞、间充质细胞、巨噬细胞、中性粒细胞、淋巴细胞和浆细胞)进行特征分析。我们使用 CD3 免疫组织化学和淋巴结切片来验证淋巴细胞的分类,而使用 F4/80 免疫组织化学来验证巨噬细胞。与许多先前的研究一致,我们发现在小鼠样本中,腺癌以巨噬细胞为主,而鳞状细胞癌则以中性粒细胞为主。在人类样本中,我们显示出中性粒细胞和淋巴细胞之间以及间充质细胞和淋巴细胞之间呈强烈负相关,而且间充质细胞的比例越高,与预后不良相关。综上所述,我们证明了这种人工智能软件在识别、定量和比较标准苏木精和伊红染色载玻片上的细胞类型分布方面的实用性。鉴于这种技术的简单性和成本效益,它可能对设计新疗法的研究人员和为患者选择有利治疗方案的临床医生都有广泛的益处。

相似文献

1
Using Artificial Intelligence to Identify Tumor Microenvironment Heterogeneity in Non-Small Cell Lung Cancers.利用人工智能识别非小细胞肺癌肿瘤微环境异质性。
Lab Invest. 2023 Aug;103(8):100176. doi: 10.1016/j.labinv.2023.100176. Epub 2023 May 12.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer.非小细胞肺癌中肿瘤内中性粒细胞与淋巴细胞比值与循环中性粒细胞与淋巴细胞比值呈正相关。
J Immunother Cancer. 2025 Jun 24;13(6):e011458. doi: 10.1136/jitc-2025-011458.
10
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益:系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.

引用本文的文献

1
Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC.整合基因组和病理特征以提高晚期非小细胞肺癌的预后精准度。
NPJ Precis Oncol. 2025 Aug 2;9(1):271. doi: 10.1038/s41698-025-01056-8.
2
Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer.缺氧肿瘤中刺激响应性聚合物纳米药物的研发及其在口腔癌治疗中的前景
Polymers (Basel). 2025 Apr 9;17(8):1010. doi: 10.3390/polym17081010.
3
A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.人工智能在肺癌临床应用的全面综述
Cancers (Basel). 2025 Mar 4;17(5):882. doi: 10.3390/cancers17050882.
4
Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response.蛋氨酸限制可降低肺癌进展并增强化疗反应。
bioRxiv. 2024 Jul 23:2024.06.25.599795. doi: 10.1101/2024.06.25.599795.
5
Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection.衰老恒河猴肺部非结核分枝杆菌感染期间的免疫和微生物变化。
mBio. 2024 Jun 12;15(6):e0082924. doi: 10.1128/mbio.00829-24. Epub 2024 May 21.
6
EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas.EZH2 抑制促进肺鳞状细胞癌的肿瘤免疫原性。
Cancer Res Commun. 2024 Feb 13;4(2):388-403. doi: 10.1158/2767-9764.CRC-23-0399.

本文引用的文献

1
Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.多梳蛋白缺失驱动 FOXP2 高表达的侵袭性状态,可被表观遗传抑制剂靶向治疗。
Nat Commun. 2023 Jan 20;14(1):336. doi: 10.1038/s41467-023-35784-x.
2
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.单细胞 RNA 测序揭示肺腺癌和鳞癌之间的异质性免疫景观。
Signal Transduct Target Ther. 2022 Aug 26;7(1):289. doi: 10.1038/s41392-022-01130-8.
3
The emerging landscape of spatial profiling technologies.新兴的空间分析技术领域。
Nat Rev Genet. 2022 Dec;23(12):741-759. doi: 10.1038/s41576-022-00515-3. Epub 2022 Jul 20.
4
Cancer Associated Fibroblasts - An Impediment to Effective Anti-Cancer T Cell Immunity.癌症相关成纤维细胞——有效抗肿瘤 T 细胞免疫的障碍。
Front Immunol. 2022 Apr 11;13:887380. doi: 10.3389/fimmu.2022.887380. eCollection 2022.
5
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.EZH2 抑制使 PIK3CA 驱动的肺肿瘤对 PI3K 抑制更敏感。
Cancer Lett. 2022 Jan 1;524:151-160. doi: 10.1016/j.canlet.2021.10.010. Epub 2021 Oct 13.
6
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.在临床前研究中,通过成像质谱细胞术对致癌基因抑制后肿瘤微环境重塑进行特征描述。
Nat Commun. 2021 Oct 8;12(1):5906. doi: 10.1038/s41467-021-26214-x.
7
Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy.EGFR 驱动的肺癌细胞的细胞起源决定了对治疗的敏感性。
Adv Sci (Weinh). 2021 Nov;8(22):e2101999. doi: 10.1002/advs.202101999. Epub 2021 Oct 7.
8
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.联合抑制 SHP2 和 CXCR1/2 可促进 NSCLC 中的抗肿瘤 T 细胞反应。
Cancer Discov. 2022 Jan;12(1):47-61. doi: 10.1158/2159-8290.CD-21-0369. Epub 2021 Aug 5.
9
Lung cancer.肺癌。
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
10
Characterization of the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma Using Imaging Mass Cytometry.利用成像质谱流式细胞术对肺鳞状细胞癌肿瘤免疫微环境进行表征
Front Oncol. 2021 Apr 1;11:620989. doi: 10.3389/fonc.2021.620989. eCollection 2021.